PE20020300A1 - Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco - Google Patents
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmacoInfo
- Publication number
- PE20020300A1 PE20020300A1 PE2001000807A PE2001000807A PE20020300A1 PE 20020300 A1 PE20020300 A1 PE 20020300A1 PE 2001000807 A PE2001000807 A PE 2001000807A PE 2001000807 A PE2001000807 A PE 2001000807A PE 20020300 A1 PE20020300 A1 PE 20020300A1
- Authority
- PE
- Peru
- Prior art keywords
- solution
- composition
- oxazolidinone
- acetamide
- drug
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 2
- 229940079593 drug Drugs 0.000 title 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- -1 2-FLUOROETHYL Chemical class 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN SOLUCION QUE COMPRENDE : a)DE 3mg/ml A 100mg/ml DE OXAZOLIDINONA SIENDO LA CONCENTRACION EFICAZ POR ENCIMA DEL LIMITE PRACTICO DE SOLUBILIDAD DEL FARMACO EN UNA SOLUCION SUSTANCIALMENTE ISOTONICA CON UN pH FISIOLOGICAMENTE COMPATIBLE DE PREFERENCIA LINEZOLIDA, N-((5S)-3-(3-FLUORO-4-(4-(2-FLUOROETIL)-3-OXOPIPERAZIN-1-IL)FENIL)-2-OXOXAZOLIDINIL-5-ILMETIL)ACETAMIDA; CLORHIDRATO DE (S)-N-[[3-[5-(4-(PIRIDIL)PIRID-2-IL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; N-[[(5S)-3-[4-(1,1-DIOXIDO-4-TIOMORFOLINIL)-3,5-DIFLUOROFENIL]-2-OXO-5-OXAZOLIDINIL]METIL]ACETAMIDA; b)UN COMPUESTO DE a, ß, g-CICLODEXTRINA, ALQUILCICLODEXTRINAS, HIDROXIALQUILCICLODEXTRINAS DE PREFERENCIA SULFOBUTILETER ß-CICLODEXTRINA UTILIZANDOSE DE 1mg/ml A 500mg/ml; c)UN AGENTE TAMPON O UN AGENTE PARA AJUSTAR LA OSMOLALIDAD. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22684600P | 2000-08-22 | 2000-08-22 | |
US28534701P | 2001-04-20 | 2001-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020300A1 true PE20020300A1 (es) | 2002-05-10 |
Family
ID=26920930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000807A PE20020300A1 (es) | 2000-08-22 | 2001-08-14 | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
Country Status (20)
Country | Link |
---|---|
US (1) | US6989381B2 (es) |
EP (1) | EP1311296B1 (es) |
JP (1) | JP2004506699A (es) |
KR (1) | KR20030027047A (es) |
AR (1) | AR030470A1 (es) |
AT (1) | ATE312627T1 (es) |
AU (2) | AU2001285087B2 (es) |
BR (1) | BR0113363A (es) |
CA (1) | CA2419597A1 (es) |
CY (1) | CY1105464T1 (es) |
DE (1) | DE60115910T2 (es) |
DK (1) | DK1311296T3 (es) |
ES (1) | ES2250461T3 (es) |
IL (1) | IL154423A0 (es) |
MX (1) | MXPA03001531A (es) |
NO (1) | NO20030787L (es) |
NZ (1) | NZ524158A (es) |
PE (1) | PE20020300A1 (es) |
PL (1) | PL365674A1 (es) |
WO (1) | WO2002015940A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
US6696426B2 (en) | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
WO2004098592A1 (ja) * | 2003-05-06 | 2004-11-18 | Senju Pharmaceutical Co. Ltd. | オキサゾリジノン誘導体含有組成物 |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
JP2013507443A (ja) * | 2009-10-13 | 2013-03-04 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | 薬学的組成物 |
WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
WO2018055581A1 (en) * | 2016-09-24 | 2018-03-29 | Jodas Expoim Private Limited | Stable injectable composition of oxazolidinone |
WO2018157043A1 (en) * | 2017-02-27 | 2018-08-30 | University Of St. Thomas | Oxazoudinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of mycobacterium tuberculosis |
CN108571074A (zh) * | 2018-05-25 | 2018-09-25 | 夏念涛 | 一种装配式钢结构矩形组合柱框架体系及其装配方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU190818B (en) * | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
HU194858B (en) * | 1982-12-03 | 1988-03-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them |
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
ZA892684B (en) | 1988-04-27 | 1989-12-27 | Warner Lambert Co | Cyclodextrin complexes of 5-aminohexahydropyrimidine compounds |
US5164510A (en) * | 1988-09-15 | 1992-11-17 | The Upjohn Company | 5'Indolinyl-5β-amidomethyloxazolidin-2-ones |
US5231188A (en) * | 1989-11-17 | 1993-07-27 | The Upjohn Company | Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
ATE196426T1 (de) * | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate |
DE69216251T2 (de) * | 1991-11-01 | 1997-05-15 | Pharmacia & Upjohn Co., Kalamazoo, Mich. | Substituierte aryl- und heteroaryl-phenyloxazolidinone |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
JP2879395B2 (ja) * | 1992-10-26 | 1999-04-05 | 富士写真フイルム株式会社 | ロダシアニン化合物及びシクロデキストリンを含有する抗癌性組成物 |
ES2062941B1 (es) * | 1993-03-15 | 1995-10-01 | Uriach & Cia Sa J | Nuevos derivados de azol activos por via oral. |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
NZ274966A (en) * | 1993-11-22 | 1998-01-26 | Upjohn Co | Substituted-hydroxyacetyl piperazine phenyl oxazolidinone derivatives, use in pharmaceutical compositions |
BE1008307A3 (fr) * | 1994-06-16 | 1996-04-02 | Europharmaceuticals Sa | Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation. |
DE4425612A1 (de) * | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
DE4425613A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | 5-gliedrige Heteroaryl-oxazolidinone |
US5807895A (en) * | 1994-11-29 | 1998-09-15 | Schwarz Pharma, Inc. | Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents |
CN1075073C (zh) * | 1995-02-03 | 2001-11-21 | 法玛西雅厄普约翰美国公司 | 杂芳环取代的苯基噁唑烷酮抗菌剂 |
ZA962214B (en) | 1995-04-10 | 1996-10-07 | Farmarc Nederland Bv | Pharmaceutical composition |
AU5780696A (en) | 1995-06-02 | 1996-12-18 | Takeda Chemical Industries Ltd. | Stabilized composition comprising an antiulcerative benzimid azole |
US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
GB9601666D0 (en) * | 1996-01-27 | 1996-03-27 | Zeneca Ltd | Chemical compounds |
HUP9600847A3 (en) | 1996-04-02 | 1999-08-30 | Human Oltoanyagtermeloe Es Gyo | Nonstochiometric compds. of primycins with ciclodextrin derivatives, pharmaceutical compns. contg. the said compds. and process for preparing them |
EP0892792B1 (en) * | 1996-04-11 | 2001-11-21 | PHARMACIA & UPJOHN COMPANY | Process to prepare oxazolidinones |
SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
DE69807200D1 (de) | 1997-02-27 | 2002-09-19 | Novo Nordisk As | Inklusionskomplexe in waessriger loesung |
US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
ATE253941T1 (de) * | 1997-06-13 | 2003-11-15 | Cydex Inc | Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden |
GB9713149D0 (en) | 1997-06-21 | 1997-08-27 | Pfizer Ltd | Pharmaceutical formulations |
CZ20001613A3 (cs) | 1997-11-07 | 2001-12-12 | Pharmacia & Upjohn Company | Způsob výroby oxazolidinonů |
HUP9701945A3 (en) | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
AU1598399A (en) | 1997-12-01 | 1999-06-16 | Schering Corporation | Injectable antifungal formulations |
PT1096934E (pt) * | 1998-07-14 | 2005-11-30 | Pharmacia & Upjohn Co Llc | Oxazolidinonas para tratamento de infeccoes oculares |
AR020660A1 (es) * | 1998-09-30 | 2002-05-22 | Alcon Lab Inc | Composiciones antibioticas para el tratamiento de ojos, oidos y nariz |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
AU780671B2 (en) * | 1999-09-13 | 2005-04-07 | Sun Pharma Global Fze | Topical treatment for prevention of ocular infections |
US6319020B1 (en) * | 1999-12-10 | 2001-11-20 | Sonic Innovations, Inc. | Programming connector for hearing devices |
PE20020044A1 (es) * | 2000-06-16 | 2002-01-30 | Upjohn Co | Tiazina oxazolidinona |
PE20020578A1 (es) * | 2000-10-10 | 2002-08-14 | Upjohn Co | Una composicion de antibiotico topico para el tratamiento de infecciones oculares |
-
2001
- 2001-08-14 PE PE2001000807A patent/PE20020300A1/es not_active Application Discontinuation
- 2001-08-20 NZ NZ52415801A patent/NZ524158A/xx unknown
- 2001-08-20 AU AU2001285087A patent/AU2001285087B2/en not_active Ceased
- 2001-08-20 BR BR0113363-2A patent/BR0113363A/pt not_active Application Discontinuation
- 2001-08-20 WO PCT/US2001/025932 patent/WO2002015940A2/en active IP Right Grant
- 2001-08-20 AU AU8508701A patent/AU8508701A/xx active Pending
- 2001-08-20 IL IL15442301A patent/IL154423A0/xx unknown
- 2001-08-20 MX MXPA03001531A patent/MXPA03001531A/es active IP Right Grant
- 2001-08-20 JP JP2002520861A patent/JP2004506699A/ja not_active Withdrawn
- 2001-08-20 DK DK01964205T patent/DK1311296T3/da active
- 2001-08-20 EP EP01964205A patent/EP1311296B1/en not_active Expired - Lifetime
- 2001-08-20 ES ES01964205T patent/ES2250461T3/es not_active Expired - Lifetime
- 2001-08-20 AT AT01964205T patent/ATE312627T1/de not_active IP Right Cessation
- 2001-08-20 KR KR10-2003-7002424A patent/KR20030027047A/ko not_active Ceased
- 2001-08-20 US US09/933,366 patent/US6989381B2/en not_active Expired - Fee Related
- 2001-08-20 CA CA002419597A patent/CA2419597A1/en not_active Abandoned
- 2001-08-20 DE DE60115910T patent/DE60115910T2/de not_active Expired - Fee Related
- 2001-08-20 PL PL01365674A patent/PL365674A1/xx not_active Application Discontinuation
- 2001-08-22 AR ARP010104011A patent/AR030470A1/es unknown
-
2003
- 2003-02-19 NO NO20030787A patent/NO20030787L/no not_active Application Discontinuation
-
2006
- 2006-03-09 CY CY20061100332T patent/CY1105464T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60115910T2 (de) | 2006-08-17 |
AU8508701A (en) | 2002-03-04 |
NZ524158A (en) | 2004-12-24 |
DE60115910D1 (de) | 2006-01-19 |
EP1311296B1 (en) | 2005-12-14 |
EP1311296A2 (en) | 2003-05-21 |
AU2001285087B2 (en) | 2006-08-03 |
US20020068720A1 (en) | 2002-06-06 |
AR030470A1 (es) | 2003-08-20 |
CY1105464T1 (el) | 2010-04-28 |
ES2250461T3 (es) | 2006-04-16 |
NO20030787D0 (no) | 2003-02-19 |
NO20030787L (no) | 2003-04-03 |
IL154423A0 (en) | 2003-09-17 |
MXPA03001531A (es) | 2003-06-24 |
CA2419597A1 (en) | 2002-02-28 |
WO2002015940A2 (en) | 2002-02-28 |
JP2004506699A (ja) | 2004-03-04 |
WO2002015940A3 (en) | 2003-02-20 |
PL365674A1 (en) | 2005-01-10 |
ATE312627T1 (de) | 2005-12-15 |
KR20030027047A (ko) | 2003-04-03 |
US6989381B2 (en) | 2006-01-24 |
DK1311296T3 (da) | 2006-04-18 |
BR0113363A (pt) | 2004-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020578A1 (es) | Una composicion de antibiotico topico para el tratamiento de infecciones oculares | |
PE20020300A1 (es) | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco | |
NO20062942L (no) | Fremgangsmate for fremstilling av en fast, oralt anvendelig farmasoytisk sammensetning | |
PE20011269A1 (es) | DERIVADOS DE 9-(5-HETEROARILTETRAHIDROFURANIL)-PURINA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA | |
JP2010527346A5 (es) | ||
UA88938C2 (ru) | Твердые фармацевтические формы для перорального введения, которые содержат ривароксабан, с модифицированным высвобождением | |
CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
PE20090123A1 (es) | Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo | |
AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
PE20020044A1 (es) | Tiazina oxazolidinona | |
RS51343B (sr) | Nova kompozicija i njena upotreba | |
JP2011530531A5 (es) | ||
JP2010500415A5 (es) | ||
PE20030007A1 (es) | Inhibidores de aldosa reductasa del grupo de las piridazinonas | |
EA200702238A1 (ru) | Комбинация, способ и композиция для лечения рака | |
MEP33308A (en) | Benzimidazole derivative and use as angiotensin ii antagonist | |
CY1106226T1 (el) | Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης | |
GEP20084306B (en) | Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them | |
ATE503748T1 (de) | Anti-krebs- und antimikrobielle oxazolidinone und analoga | |
NO20044672L (no) | Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner | |
PE20020295A1 (es) | Composiciones de oxazolidinona, ampicilina y sulbactam | |
JP2002520359A5 (es) | ||
GEP20237580B (en) | Cyclodextrin-based formulation of a bcl-2 inhibitor | |
NZ609964A (en) | Pharmaceutical compositions | |
NO20072303L (no) | Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal | ||
FG | Grant, registration | ||
FD | Application declared void or lapsed |